AGL vs LQDA
Agilon Health, Inc. vs Liquidia Corporation — AI-powered side-by-side comparison
AGL
Agilon Health, Inc.
55
Watch
VS
LQDA
Liquidia Corporation
68
Buy
| Metric | AGL | LQDA |
|---|
| AI Score |
55
|
68
|
| Price |
$86.88
|
$88.09
|
| P/E Ratio |
-5.62×
|
368.26×
|
| ROE |
-319.8%
|
-154.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
91.8%
|
| Debt / Equity |
0.15×
|
1.70×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
38.0
|
55.0
|
| Beta |
3.054
|
0.572
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for AGL versus LQDA.
LQDA leads by 13 points.
LQDA scores 68/100 (Buy) versus AGL at 55/100 (Watch).
AGL Committee View
50% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 54.0% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 54.0% signals elevated volatility — Risk
LQDA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 46.8% shows genuine earnings power backing the valuation — Value
- Revenue growing 1936.7% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 362.9 is expensive by classic value standards — Value
- Price-to-book of 12.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical